New Product Due Diligence and Approval
Quick Answer
Under the FINRA supervisory system and internal supervisory controls requirements, a member firm must vet every new product (and every material modification of an existing product) through a formal review committee before offering it to customers. The committee documents product mechanics, risks, appropriate-customer profiles, conflicts, and operational capacity, then approves, conditions, or rejects the product. Complex products (structured notes, leveraged and inverse ETFs, reverse convertibles) trigger heightened due diligence and rep-level training before any recommendation.
The new-product review framework is the firm-level gate that feeds the reasonable-basis prong of suitability: a product the firm cannot understand cannot be recommended to anyone.
The Supervisory Mandate
The new-product framework rests on two FINRA requirements covered in detail in Unit 3:
- The FINRA supervisory system requirement directs each member to establish, maintain, and enforce a supervisory system reasonably designed to achieve compliance with securities laws and FINRA rules. The duty extends to the products and services the firm offers
- The FINRA internal supervisory controls requirement directs designated principals to test and verify that the firm's written supervisory procedures (WSPs), including new-product procedures, are reasonably designed; results feed an annual report to senior management
Together, the supervisory system and internal supervisory controls requirements require the firm to define how products are vetted, who approves, what training is required, and how risk is reassessed post-launch through written procedures that are then tested and reported.
The New-Product Review Committee
A formal new-product review committee should reach a documented decision before any rep recommends a new product or a materially modified existing product to customers.
Committee Composition
The committee should include representatives from all relevant business areas:
- Compliance, Legal, Risk Management
- Finance, Operations, Trading
- Marketing, Sales Supervision
- At least one member of senior management with formal decision-making authority
Possible Outcomes
The committee must reach a formal decision to approve, disapprove, or table the product. Approval may be conditioned on limitations, including:
- Restrictions on whom the product may be sold to (e.g., speculative-objective customers only, minimum net worth, accredited-investor only)
- Mandatory training for any rep selling the product
- Holding-period or rebalancing alerts for time-sensitive products (e.g., daily-reset leveraged ETFs)
- Limited rollout to a subset of branches or producers before broader release
Exam Tip: Gotchas
- A "material modification" of an existing product triggers the new-product review the same as a brand-new product. A change to the embedded derivatives, payoff formula, fee structure, or eligible-investor class is material; cosmetic prospectus updates are not. A firm cannot bypass the committee by labeling a redesigned product as a "version update."
- A product approved for "speculative" customers only must be enforced through suitability controls and exception reports, not just disclosed in the WSP. If reps sell the product to "income" or "preservation" customers without a documented exception, the firm has a supervisory-system failure plus a suitability-rule violation even if each individual sale was disclosed.
Required Due-Diligence Topics
The committee should document its analysis of each topic below. A blank or boilerplate entry is itself a supervisory red flag.
| Topic | What the Committee Documents |
|---|---|
| Product structure and mechanics | How payoffs are calculated, embedded derivatives, fees and expense layers, tax treatment |
| Risk characteristics | Market risk, credit risk, liquidity risk, leverage, complexity, correlation behavior |
| Appropriate accounts | Customer profiles (objectives, risk tolerance, experience, time horizon, liquidity needs) the product fits, and which it does not |
| Issuer / sponsor due diligence | Financial condition, regulatory history, prior product performance |
| Marketing and disclosure | Whether prospectus / offering materials accurately convey risk; whether marketing materials comply with the FINRA communications-with-the-public framework |
| Conflicts of interest | Compensation differentials, revenue-sharing, affiliated-underwriter relationships |
| Operational capability | Whether systems can clear, settle, custody, value, and report on the product |
| Post-approval review | Periodic reassessment, exception reports, complaint trends, customer-outcome data |
Think of it this way: The due-diligence checklist is the firm's case file. If a customer later complains, the firm's defense rests on the file showing that the product's risks were understood, that the customer profile was identified, and that the surveillance reports caught the issue before regulators did.
Application to Complex Products
"Complex products" carry heightened supervisory expectations because their payoffs, leverage, or holding-period sensitivity are not intuitive to most retail customers.
Examples of Complex Products
- Structured products (issuer notes with derivatives-linked payoffs)
- Leveraged and inverse ETFs / ETPs (daily-reset products targeting 2x, 3x, -1x of an index)
- Principal-protected notes
- Commodity futures-linked products
- Reverse convertibles
- Volatility-linked products
- Non-traditional and alternative funds (e.g., interval funds, business development companies, commodity-pool funds)
Heightened Expectations
For each complex product, the firm should impose additional supervisory layers:
- Enhanced due diligence beyond the standard committee checklist
- Specific training for any rep recommending the product
- Product-by-product approval (no blanket category approval; each issuer's structured note is a separate product)
- Enhanced supervision of recommendations, including holding-period monitoring for daily-reset products
The Daily-Reset Problem
Leveraged and inverse ETFs reset their leverage daily. Over multiple days, the compounding effect causes the product's return to diverge from the simple multiple of the index return.
- A 2x leveraged ETF on an index that goes up 5% then down 5% over two days does not return zero (which a 1x-then-flat path would suggest); it returns slightly less than zero because the daily reset compounds
- Over volatile multi-week periods, the divergence can be substantial: an investor in a 3x leveraged ETF for a month may underperform 3x the monthly index return materially
WSPs for leveraged / inverse ETFs should require alerts on extended holding by retail customers (e.g., a flag at any holding period beyond the daily horizon the product is designed for).
Exam Tip: Gotchas
- Leveraged and inverse ETFs are designed for one-day holding periods. Their multi-day returns diverge from the simple multiple of the index return because of daily compounding. A WSP that approves leveraged ETFs for general retail use without holding-period alerts is presumptively inadequate even if every individual sale appeared suitable at the moment of recommendation.
- "Complex product" approval is product-by-product, not category-by-category. A firm that approves "structured notes" as a category and then sells any issuer's structured note has not done product-level due diligence. Each issuer's note (different reference asset, different payoff formula, different barrier level) is a separate supervisory event.